Based on the different pathways activated in breast cancer cells by cholesterol or mevalonate and given the pivotal role that they play in promoting tumor proliferation (in particular, ERbB2/HER2 and NOTCH2 signaling), we evaluated the effects of cholesterol or mevalonate treatment on cell cycle progression. This evidence concerns the gene NOTCH2 and breast carcinoma.